Form 4: Xilio Therapeutics COO Acquires 52,000 Stock Options

Christopher James Frankenfield, Chief Operating Officer of Xilio Therapeutics, Inc., was granted 52,000 stock options on August 3, 2024.

Summary

• Christopher James Frankenfield, the Chief Operating Officer of Xilio Therapeutics, Inc., was granted 52,000 stock options on August 3, 2024.
• The options have an exercise price of $0.895.
• The options vest in equal monthly installments starting September 1, 2024, and continuing through August 1, 2028.
• The options expire on August 2, 2034.

Sentiment

Score: 6

Explanation: The document is a routine filing related to stock option grants, which is generally neutral. It indicates alignment of management with shareholder interests, which is mildly positive.

Positives

• The grant of stock options to the COO aligns his interests with those of the shareholders, incentivizing him to improve the company's performance.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize executives and align their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotech industry.
• Companies like Amgen, Gilead, and Regeneron also use stock options to incentivize their executives.
• The vesting schedule and exercise price are generally in line with industry standards for similar-sized companies.

Stakeholder Impact

• Shareholders may view the option grant as a positive sign, indicating that the company is incentivizing its executives to create value.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates